ProPhase Labs Announces Significant Laboratory Expansion
Retrieved on:
Monday, June 13, 2022
DNA sequencing, NGS, TK, Whole genome sequencing, Company, Hemostasis, Research, Marketing, Food, Genetic, Immunoassay, OTC, Hematology, Platelet, Genetics, CLIA, RNA, Environment, Nebula Genomics, Failure, COVID-19 testing, Nasdaq, Gene, Urine test strip, Physician, GLOBE, FDM, Bleeding time, Private Securities Litigation Reform Act, RT-PCR, DNA, Laboratory, Media relations, PCR, COVID-19, Prothrombin time, Risk, Prophase, Chromosome, Acquisition, NASDAQ, SEC, Severe acute respiratory syndrome coronavirus 2, Institution, Inherited disorders of trafficking, Heart, Thromboplastin, Dietary supplement, Genomics, WGS, University, Antibiotics, Pharmaceutical industry, Blood product, Vaccine
Garden City, NY, June 13, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that it has partnered with world-renowned healthcare diagnostics innovators for new clinical chemistry, immunoassay, hematology, hemostasis and urinalysis analyzers as part of its plan to significantly expand its in-house clinical testing capabilities. State-of-the-art clinical testing equipment has been procured and a new lease executed for additional space at the company’s corporate headquarters in Garden City, New York. Plans are also under way to expand the company’s in-house genomics testing offerings.
Key Points:
- ProPhase Labs relocated to its current headquarters in January 2021 and built from scratch a 25,000 square foot state-of-the-art CLIA certified laboratory to support the companys growing COVID-19 testing franchise.
- Ted Karkus, ProPhase Labs Chief Executive Officer, commented, We are very excited to broaden ProPhases testing capabilities at our Garden City headquarters.
- ProPhase Diagnostics, Inc. (ProPhase Diagnostics), a wholly-owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19).
- ProPhase Precision Medicine, Inc. (ProPhase Medicine), a wholly-owned subsidiary of ProPhase, focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA.